Therapeutic value of pharmaceutical preparations

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Nowadays, the concept of therapeutic value of pharmaceutical preparations goes beyond the traditional assessment of their efficacy and safety, integrating pharmacoeconomic, organizational, and patient-oriented aspects. Current review examines the main approaches to defining and measuring drug value, from international experience to Russian regulatory practice (lists of vital and essential drugs, lists of expensive drugs, minimum product range, clinical recommendations). Particular attention is paid to three levels of therapeutic value assessment: strategic (government policy and lists), institutional (medical organization level), and patient (individual decision on therapy selection at the patient’s bedside). Pharmacological paradigm is presented as a Russian contribution to the development of the concept of therapeutic value, uniting all its levels into a unified system for supporting a drug throughout its life cycle. Prospects for integrating real-world clinical practice data, personalized medicine, and new financing models into the national healthcare system are discussed. Emphasis on the practical significance of the therapeutic value concept for general practitioners is made.

全文:

受限制的访问

作者简介

Maxim Frolov

Volgograd State Medical University of the Ministry of Healthcare of Russia

编辑信件的主要联系方式.
Email: maxim.frolov@internet.ru
ORCID iD: 0000-0002-0389-560X

MD, PhD (Medicine), associate professor of the Department of clinical pharmacology and intensive care, head of the Department of pharmacoeconomics, digital medicine, and artificial intelligence of Scientific Center for Innovative Pharmaceutical Preparations with Pilot Production, secretary and head of the Expert Group of Specialized Clinical Pharmacology Commission of the Ministry of Healthcare of Russia

俄罗斯联邦, Volgograd

参考

  1. Полякова О.А., Остроумова О.Д., Араблинский А.В. Лекарственная безопасность и полиморбидность как важные составляющие рациональной фармакотерапии в кардиологии. Терапия. 2022;8(4):141–148. [Polyakova OA, Ostroumova OD, Arablinsky AV. Drug safety and polymorbidity as important components of rational pharmacotherapy in cardiology. Terapiya = Therapy. 2022;8(4):141–148 (In Russ.)]. EDN PJJAGV. https://doi.org/10.18565/therapy.2022.4.141-148
  2. Драпкина О.М., Авдеев С.Н., Будневский А.В., Концевая А.В., Шаповалова М.М., Трибунцева Л.В. Мультиморбидность при бронхиальной астме. Профилактическая медицина. 2024;27(1):84–89. [Drapkina OM, Avdeev SN, Budnevsky AV, Kontsevaya AV, Shapovalova MM, Tribuntceva LV. Multimorbidity in asthma. Profilakticheskaya meditsina = Russian Journal of Preventive Medicine. 2024;27(1):84–89 (In Russ.)]. EDN WGCNXU. https://doi.org/10.17116/profmed20242701184
  3. Radcliffe E, Saucedo AR, Howard C, Sheikh C, Bradbury K, Rutter P et al. Development of a complex multidisciplinary medication review and deprescribing intervention in primary care for older people living with frailty and polypharmacy. PLoS One. 2025;20(4):e0319615. PMID: 40261878. PMCID: PMC12013936. https://doi.org/10.1371/journal.pone.0319615
  4. Varghese D, Ishida C, Patel P, Haseer Koya H. Polypharmacy. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. URL: https://www.ncbi.nlm.nih.gov/books/NBK532953/ (date of access – 22.10.2025).
  5. Karaflou M, Goulis DG. The growing challenge of aging populations: Addressing health and societal impacts. Maturitas. 2025;202:108720. PMID: 40934636. https://doi.org/10.1016/j.maturitas.2025.108720
  6. Бернс С.А., Савичева А.А., Исайкина О.Ю., Веремеев А.В., Горшков А.Ю., Драпкина О.М. Биологический возраст: проблемы и перспективы. Обзор литературы. Кардиоваскулярная терапия и профилактика. 2024;23(12):290–298. [Berns SA, Savicheva AA, Isaykina OYu, Veremeev AV, Gorshkov AYu, Drapkina OM. Biological age: problems and prospects. Literature review. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2024;23(12):290–298 (In Russ.)]. EDN: DWZUMI. https://doi.org/10.15829/1728-8800-2024-4254
  7. Кобалава Ж.Д., Петрухина И.К., Лебедев П.А., Блинкова П.Р., Рязанова Т.К., Гладунова Е.П., Паранина Е.В. Структура популяционного потребления антигипертензивных и гиполипидемических лекарственных препаратов в Российской Федерации (СПАРДЕК). Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2025;18(2):175–183. [Kobalava ZhD, Petrukhina IK, Lebedev PA, Blinkova PR, Ryazanova TK, Gladunova EP, Paranina EV. Population consumption of antihypertensive and lipid-lowering drugs in the Russian Federation (SPARDEC). Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025;18(2):175–183 (In Russ.)]. EDN: UHVTDF. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.253
  8. Лемешко В.А., Мусина Н.З., Омельяновский В.В. Определение терапевтической ценности противоопухолевых лекарственных препаратов. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2020;13(3):262–269. [Lemeshko VA, Musina NZ, Omelyanovskiy VV. Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(3):262–269 (In Russ.)]. EDN: MAWVMO. https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.056
  9. Su J, Yang L, Sun Z, Zhan X. Personalized drug therapy: Innovative concept guided with proteoformics. Mol Cell Proteomics. 2024;23(3):100737. PMID: 38354979. PMCID: PMC10950891. https://doi.org/10.1016/j.mcpro.2024.100737
  10. Камкин Е.Г., Каракулина Е.В., Астапенко Е.М., Гульшина В.А., Москалев А.А., Старовойтова А.С. с соавт. Программа лекарственного обеспечения пациентов в рамках федерального проекта «Борьба с сердечно-сосудистыми заболеваниями»: стратегия реализации, результаты и перспективы. Российский кардиологический журнал. 2025;30(6):7–17. [Kamkin EG, Karakulina EV, Astapenko EM, Gulshina VA, Moskalev AA, Starovoitova AS et al. Preferential drug program for patients within the federal project for control of cardiovascular diseases: Implementation strategy, results and prospects. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2025;30(6):7–17 (In Russ.)]. EDN: TYQUTG. https://doi.org/10.15829/1560-4071-2025-6391
  11. Колбин А.С., Гомон Ю.М., Касимова А.Р., Курылев А.А., Бем А.Э. Реальная практика проведения клинико-экономических исследований лекарственных средств, входящих в федеральную программу высокозатратных нозологий. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2022;15(1):87–105. [Kolbin AS, Gomon YuM, Kasimova AR, Kurylev AA, Bem AE. The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):87–105 (In Russ.)]. EDN: VPTGWY. https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.107
  12. Недогода С.В., Саласюк А.С., Авдеев С.Н., Барыкина И.Н., Лутова В.О., Попова Е.А. Анализ клинико-экономической эффективности применения бенрализумаба в сравнении со стандартной терапией у пациентов с тяжелой бронхиальной астмой. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2023;16(4):527–536. [Nedogoda SV, Salasyuk AS, Avdeev SN, Barykina IN, Lutova VO, Popova EA. Analysis of the clinical and economic effectiveness of using benralizumab in comparison with standard therapy in patients with severe bronchial asthma. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(4):527–536 (In Russ.)]. EDN: TQJMSR. https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.223
  13. Колесник Т.И., Габбасова Л.А., Павликова Е.П. Методы оценки качества фармакотерапии, как инструменты повышения эффективности и безопасности лечебного процесса. Качественная клиническая практика. 2025;(3):97–105. [Kolesnik TI, Gabbasova LA, Pavlikova EP. Methods for assessing the quality of pharmacotherapy as tools for improving the effectiveness and safety of treatment interventions. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2025;(3):97–105 (In Russ.)]. EDN: LYYFLW. https://doi.org/10.37489/2588-0519-2025-3-97-105
  14. He W, Li M, Cao L, Liu R, You J, Jing F et al. Introducing value-based healthcare perspectives into hospital performance assessment: A scoping review. J Evid Based Med. 2023;16(2):200–15. PMID: 37228246. https://doi.org/10.1111/jebm.12534
  15. Khalil H, Ameen M, Davies C, Liu C. Implementing value-based healthcare: A scoping review of key elements, outcomes, and challenges for sustainable healthcare systems. Front Public Health. 2025;13:1514098. PMID: 40270723. PMCID: PMC12014573. https://doi.org/10.3389/fpubh.2025.1514098
  16. Хайруллин И.И., Омельяновский В.В., Гостищев Р.В., Агафонова Ю.А., Гилязетдинова Н.С., Михайлов И.А. Результаты адаптации инструментов стандартизации ценностно-ориентированных исходов: анализ наборов параметров ICHOM. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2025;18(2):219–231. [Khayrullin II, Omelyanovskiy VV, Gostishchev RV, Agafonova JA, Giliazetdinova NS, Mikhailov IA. Results of adaptation of tools for standardizing value-based outcomes: Analysis of ICHOM standard sets. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemiologiya = Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2025;18(2):219–231 (In Russ.)]. EDN: MDLEIH. https://doi.org/10.17749/2070-4909/farmakoekonomika.2025.319
  17. Яковлев Д.С., Серегина М.С., Науменко Л.В., Таран А.С., Сиротенко В.С., Мальцев Д.В. с соавт. Лиганды аденозиновых рецепторов: переоценка клинического потенциала, перспективы поиска и фармакологического изучения. Экспериментальная и клиническая фармакология. 2023;86(11S):164. [Yakovlev DS, Seregina MS, Naumenko LV, Taran AS, Sirotenko VS, Maltsev DV et al. Adenosine receptor ligands: Reassessment of clinical potential, prospects for search and pharmacological study. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2023;86(11S):164 (in Russ.)]. EDN: NDHMAK. https://doi.org/10.30906/ekf-2023-86s-164
  18. Logroscino G. Randomized clinical trial (RCT): An overview. eNeurologicalSci. 2025;38:100547. PMID: 39866831. PMCID: PMC11757218. https://doi.org/10.1016/j.ensci.2025.100547
  19. Гольдина Т.А., Колбин А.С., Белоусов Д.Ю., Боровская В.Г. Обзор исследований реальной клинической практики. Качественная клиническая практика. 2021;(1):56–63. [Goldina TA, Kolbin AS, Belousov DYu, Borovskaya VG. Review of real-world data study. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2021;(1):56–63 (In Russ.)]. EDN: SCQIYS. https://doi.org/10.37489/2588-0519-2021-1-56-63
  20. Бушева Т.И., Касимова А.Р., Колбин А.С., Пшеничников А.Н. Суррогатные конечные точки в анализе экономической эффективности для использования при оценке медицинских технологий. Реальная клиническая практика: данные и доказательства. 2025;5(2):16–27. [Busheva TI, Kasimova AR, Kolbin AS, Pshenichnikov AN. Surrogate endpoints in cost-effectiveness analysis for use in medical technology assessment. Real’naya klinicheskaya praktika: dannyye i dokazatel’stva = Real-World Data & Evidence. 2025;5(2):16–27 (In Russ.)].
  21. Institute for Clinical and Economic. 2020–2023 Value Assessment Framework. URL: https://icer.org/wp-content/uploads/2020/10/ICER_2020_2023_VAF_102220.pdf (date of access – 22.10.2025). EDN: ZVVPHM. https://doi.org/10.37489/2782-3784-myrwd-071
  22. Spencer A, Rivero-Arias O, Wong R, Tsuchiya A, Bleichrodt H, Edwards RT et al. The QALY at 50: One story many voices. Soc Sci Med. 2022;296:114653. PMID: 35184921. https://doi.org/10.1016/j.socscimed.2021.114653
  23. Milliman report. Pyenson B, Smith R, Halpren A, Entezarian P. A new framework for quantifying healthcare value using real-world evidence. August 2024. URL: https://www.milliman.com/en/insight/new-framework-healthcare-value-real-world-evidence (date of access – 22.05.2025).
  24. Бушева Т.И., Курылев А.А. Обзор методов оценки экономической эффективности медицинских вмешательств. Реальная клиническая практика: данные и доказательства. 2024;4(4):3–10. [Busheva TI, Kurylev AA. Review of methods for assessing the cost-effectiveness of medical interventions. Real’naya klinicheskaya praktika: dannyye i dokazatel’stva = Real-World Data & Evidence. 2024;4(4):3–10 (In Russ.)]. EDN: FKIIZZ. https://doi.org/10.37489/2782-3784-myrwd-057
  25. Calder RA, Patel JJ. Statistical thinking part 2: Relative risk, absolute risk, and number needed to treat. WMJ. 2024;123(4):324–27. PMID: 39284097.
  26. Ganesh V, Sahni N, Garg R. Understanding number needed to treat (NNT): A practical guide for anaesthesia and critical care clinicians. Indian J Anaesth. 2025;69(10):969–74. PMID: 40979769. PMCID: PMC12445750. https://doi.org/10.4103/ija.ija_1000_25
  27. Horita N, Yamamoto S, Mizuki Y, Kawagoe T, Mihara T, Yamashiro T. Minimal clinically important difference (MCID) of effect sizes other than mean difference. J Clin Quest. 2024;1(3):116–27. https://doi.org/10.69854/jcq.2024.0016
  28. Ким О.Т. Безопасность пациентов как приоритет мирового здравоохранения. Кардиоваскулярная терапия и профилактика. 2022;21(10):67–79. [Kim OT. Patient safety as a global health priority. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2022;21(10):67–79 (In Russ.)]. EDN RUCYXO. https://doi.org/10.15829/1728-8800-2022-3427
  29. Trowman R, Migliore A, Ollendorf DA. Health technology assessment 2025 and beyond: Lifecycle approaches to promote engagement and efficiency in health technology assessment. Int J Technol Assess Health Care. 2023;39(1):e15. PMID: 36815310. PMCID: PMC11574536. https://doi.org/10.1017/S0266462323000090
  30. Андреев Д.А., Николаев А.А. Методики оценки технологий здравоохранения. Экспертный обзор. М.: ГБУ «НИИОЗММ ДЗМ». 2025; 35 с. [Andreev DA, Nikolaev AA. Methodologies for assessing health technologies. Expert review. Moscow: Research Institute for Healthcare Organization and Medical Management of the Department of Healthcare of Moscow. 2025; 35 pp. (In Russ.)]. ISBN 978-5-907952-06-5
  31. Jen MH, Mt-Isa S, Chu H, Bridges I, Cai Z, Dunger-Baldauf C et al. The current landscape of HTA framework and key challenges. Stat Biopharm Res. 2025: 1–15. https://doi.org/10.1080/19466315.2025.2495307
  32. World Health Organization. Essential medicines. 25 September 2024. URL: https://www.who.int/news-room/fact-sheets/detail/essential-medicines (date of access – 22.10.2025).
  33. Costa E, Del Grosso V, Cappello B, Genazzani AA, Huttner B, Leufkens HGM et al. Medicines not recommended for inclusion in the WHO essential medicines list: A retrospective observational study. Front Med (Lausanne). 2025;12:1517020. PMID: 40166059. PMCID: PMC11955596. https://doi.org/10.3389/fmed.2025.1517020
  34. Петров В.И. Фармакологистика – новая парадигма в клинической фармакологии. Вестник Волгоградского государственного медицинского университета. 2022;19(2):3–6. [Petrov VI. Pharmacologistics – a new paradigm in clinical pharmacology. Vestnik Volgogradskogo gosudarstvennogo meditsinskogo universiteta = Journal of Volgograd State Medical University. 2022;19(2):3–6 (In Russ.)]. EDN: KXRRNF. https://doi.org/10.19163/1994-9480-2022-19-2-3-6
  35. Петров В.И., Тюренков И.Н., Куркин Д.В. От молекулы до лекарства. фармакологистический подход. Вестник Российской академии медицинских наук. 2023;78(1):53–61. [Petrov VI, Tyurenkov IN, Kurkin DV. From molecule to drug. Pharmaceutical logistics approach. Vestnik Rossiyskoy akademii meditsinskikh nauk = Annals of the Russian Academy of Medical Sciences. 2023;78(1):53–61 (In Russ.)]. EDN: QMAQGB. https://doi.org/10.15690/vramn2237

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2025